From lab to market.

Introducing one of the world's largest development pipelines for Advanced Therapy Medicinal Products (ATMP).

> Commercialising Technology



Introducing one of the world's largest ATMP pipelines

University College London (UCL) is at the heart of a world-leading integrated ecosystem of research, innovation, clinical trialling and commercialisation for advanced therapies.

In addition to **world-class researchers**, front line practitioners and trialling facilities at UCL's leading partner hospitals, this ecosystem is supported by UCL's Translational Research Office, Therapeutic Innovation Networks (TINs) and UCL's commercialisation operation UCL Business (UCLB). The result of this connected community is an unrivalled advanced product development pipeline, with **over 50 projects** in discovery, **26 in preclinical/IND** enabling studies, **28 currently in Phase I/II** clinical trials; **3 in Phase III** clinical trials and one globally important treatment for haemophilia (Roctavian[™]) already licenced in the U.S and EU.

Taken together, this represents one of the world's highest quality research, development, and commercialisation operations, optimising the successful journey of ground-breaking new advanced therapies from lab to patients and market.



Publicly funded academic research compliments our licensing activities and commercial spinout creation

The scale of UCL's support for ATMP development collectively de-risks the pipeline thereby reducing investment risk. This maximises successful commercialisation and is a result of robust financial support by both public and private investment.

Our extensive portfolio of publicly funded projects, along with **UCL and UCLB's** Proof of Concept funding schemes supports early and mid-stage academic research, ensuring our development pipeline is second to none. The current active portfolio has, **over £58M** of public funding invested in Phase I/II trials and **over £20M** invested in preclinical stage projects, whilst more than 50 projects are in discovery phase, supported by smaller grants.

Disease Area	Discovery (50 Projects > £2M)	Preclinical (26 Projects > £20M)	Phase I/II (16 Projects > £58M)
Haematology/Oncology	09	05	11
Rare Disease	12	07	02
Neurology	16	11	01
Metabolic & Immunology	09	02	01
Ophthalmology	04	01	01

Extensive pipeline de-risked through significant peer reviewed public funding investment - opportunity to partner. Portfolio information accurate as of December 23.

Coordinated support leads to successful commercialisation

Our commercial portfolio maps onto UCL's key areas of clinical expertise in Rare Diseases, Ophthalmology Haematology/Oncology, Neurology and Immunology.

We work with commercial partners either by forming spinout business or licensing technologies through UCLB, attracting external/commercial funding to take promising therapeutics through clinical trials to launch.

UCL, UCLB and our hospital partners' extensive professional support – from science-trained business managers, translational research experts and clinical facilities and units – supports this process every step of the way, helping to de-risk projects and maximise venture capital investment.




Extensive professional support and know-how has de-risked projects to attract significant VC investment. Portfolio information accurate as of December 23.



Scale and collaboration to de-risk clinical delivery

Over 50% of the UKs entire ATMP academically sponsored clinical trials and **over 40%** of all UK's commercial sponsored ATMP trials are conducted via UCL partner hospitals.

Our network of clinical trial centres and specialist medical facilities provide the infrastructure to deliver trials at **scale and at pace**, while our close links with research centres across the world enables effective co-ordination across multiple territories.





Talk to us

For information about translational research and industry-academia collaborations, speak to the TRO -Dr Jane Kinghorn, Director, <u>i.kinghorn@ucl.ac.uk</u>



For information about commercialisation, speak to UCLB - Dr Rick Fagan, <u>r.fagan@uclb.com</u>



Join TINs

Scan to enrol as a member of the UCL Therapeutic Innovation Networks (TINs) and receive news and event invitations about therapeutic innovations at UCL. <u>tins@ucl.ac.uk</u>







